SCTX CRISPR therapies show promise for cardiovascular prevention
SCTX’s novel CRISPR-based platform for cardiovascular and metabolic diseases is advancing, with lead programs targeting LDL-C, Lp(a) and triglycerides. Early data point to durable efficacy and safety, backed by major partnerships.
A novel CRISPR-based platform is advancing genetic medicines for cardiovascular and metabolic diseases, with lead programs targeting LDL-C, Lp(a), and triglycerides.
Early data show durable efficacy and safety, supported by major partnerships and a strong pipeline.Original document: Scribe Therapeu…